Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CTXR | US
0.00
0.60%
Healthcare
Biotechnology
30/06/2024
30/08/2024
0.57
0.56
0.59
0.56
Citius Pharmaceuticals Inc. a late-stage pharmaceutical company engages in the development and commercialization of critical care products focusing on oncology products anti-infectives products in adjunct cancer care prescription products and stem cell therapy. It is developing five proprietary products comprising I/ONTAK an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford New Jersey.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
111.4%1 month
111.0%3 months
100.8%6 months
90.1%-
9.50
1.20
0.00
0.00
-2.74
-
-
-41.07M
103.01M
103.01M
-
-
-
-
-41.49
4.49
7.29
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.12
Range1M
0.50
Range3M
0.57
Rel. volume
0.15
Price X volume
176.17K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ELEDON PHARMACEUTICALS INC | ELDN | Biotechnology | 2.81 | 111.43M | -1.40% | 6.24 | -7.70% |
Agenus Inc | AGEN | Biotechnology | 5.15 | 111.10M | 3.21% | n/a | -170.56% |
Leap Therapeutics Inc | LPTX | Biotechnology | 2.9 | 110.97M | 2.47% | n/a | 0.73% |
Regulus Therapeutics Inc | RGLS | Biotechnology | 1.68 | 109.98M | 1.82% | n/a | 1.45% |
bluebird bio Inc | BLUE | Biotechnology | 0.5615 | 108.22M | -5.22% | n/a | 136.48% |
CRDF | CRDF | Biotechnology | 2.31 | 107.53M | 0.43% | n/a | 3.52% |
Checkpoint Therapeutics Inc | CKPT | Biotechnology | 2.35 | 105.79M | 0.43% | n/a | 0.00% |
Adlai Nortye Ltd. | ANL | Biotechnology | 2.8334 | 104.55M | 3.03% | n/a | 38.82% |
Dermira Inc | DERM | Biotechnology | 4.98 | 103.22M | -4.41% | 38.31 | 201.92% |
Seer Inc. | SEER | Biotechnology | 1.68 | 103.20M | -1.75% | n/a | 7.43% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Saga Communications Inc | SGA | Broadcasting - Radio | 14.72 | 92.17M | -2.06% | 14.72 | 7.10% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.38 | 76.89M | 5.34% | n/a | 268.43% |
Emmis Communications Corporation | EMMS | Broadcasting - Radio | 4.7 | 57.98M | -1.05% | n/a | 54.59% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.68 | 39.85M | -1.12% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.6131 | 18.67M | -4.20% | n/a | 204.46% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.391 | 3.72M | -6.28% | n/a | 19.98% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.45 | 3.70M | 13.28% | n/a | 9.62% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.74 | 0.97 | Cheaper |
Ent. to Revenue | - | 3,681.29 | - |
PE Ratio | - | 39.83 | - |
Price to Book | 1.20 | 14.54 | Cheaper |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 100.79 | 76.13 | Riskier |
Debt to Equity | 0.00 | -2.05 | Expensive |
Debt to Assets | 0.00 | 0.25 | Cheaper |
Market Cap | 103.01M | 4.04B | Emerging |